"id","versionIdentifier","uuid:ID","instanceType","rationale"
"StudyVersion_1","2","d3e02eb4-8d39-4833-a9f1-cb87625782cd","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
